Mesoblasts last quarter expenses were $20.7m with $136.4m in the bank at the end of the quarter (30 June). So based on this Mesoblast have 19.7 months of cashflow to January 2023.
Given all the potential for Novartis to sign, covid eua, CHF partner, CLBP Milestones and Gvhd approval expected by Q2 2022, Mesoblast may well have had its last capital raise.
Noting that until a product is approved in the US, the company will not turn a profit and will require more capital.
Mesoblasts last quarter expenses were $20.7m with $136.4m in the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.040(3.88%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $4.797M | 4.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 126568 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 9484 | 17 |
View Market Depth
| Last trade - 14.53pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |